U.S. Markets closed

Galena Biopharma, Inc. (GALE)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.5660.000 (0.000%)
At close: 4:00PM EDT
People also watch
  • All right. Ill fill the void left by jimmy
    Will all the short trolls with multiple ids deny they are paid to post. Its got to be a buy sign that short interest has declined by 5 shares. Lead investigators know the truth. Gale has a miniscule cash burn number and has a 20 year runway. They moved headquarters 2 years ago to be close to roche and since theyre in a quiet period they cant announce the takeover for 87.5 Billion (not including milestone payments)
  • James - You haven't accused anyone of being short in 4 days or paid to post? What gives?
  • Has James followed Antoniass out the door?
  • Have they announced a REVERSE SPLIT yet? The 180 grace period expires in September.
  • James. What does the million dollar plus settlement do to your idiotic cash flow numbers?
  • Has James finally thrown in the towel?
  • When is the BANKRUPTCY filing?
  • Here we go. Oh wait. Its down again.
  • I think GALE is worth .29, and hopefully a more realistic valuation will set in after the next earnings report - cash burn is going to be huge!

    I find it hard to believe that these pumpers want desperate cancer patients to take snake oil. It's unbelievable greed! God willing if any of the pumpers, or their loved ones, get a brutal diagnosis of cancer, they won't have snake oil salesmen trying to leech them of all their hope all in the name of greed. Disgusting scammers keep talking about a "super nova", like lottery players, and don't give a damn about anything but their own pocketbooks.
  • Boiler room short troll at work✅And Still NOT ONE DENIAL IT IS PAID TO POST SHORT LIES AND DiSINFORMATION *This is a repost * 1 PAID BOILER ROOM SCAMMER 50 fake id'sMixMucho*Hugo*NIce* Dance*G*PennyPineALI George NO DENIALS * Nasdaq CONFIRMS SHORT FUNDS ARE COVERING?* Note Not 1 denial from the 50 PAID Ids * This was posted days ago STILL NOT 1 Denial even with the 1,000's of posts * Short Funds Pay 2 Manipulate this board w/lies & distortions * They OVER Shorted Gale Well Below True Market Value * Millions of Shares to cover *All the Same 1 PAID Basher Dance Sam Ken Riot Phil Moonie Ignatius Mucho Setto Pine Pernn PNNK bone David George wrongway Nice Bohemian Cynic Hugo jenny Milliondollar Venez Ali G Sayed Gthp Jenny G Ken Dead Hugo Penny FinnPhil David Options Sam Mucho Nothingbut Phil Louis Mix ignatius Ken Nice Bohemian Venez Nothingbut ALI Riot Setto Pine phil Lou Ken G Riot Moonie Mucho Ali Sayed AND NOTE there will be no denials among the 1,000's of posts - Gale is trading below true market value of assets
    This is what the Primary investigator said last month ---AFTER seeing the Single Blind Trial Data.
    Combinations ‘Likely the Way Forward’ for Breast Cancer Immunotherapy Research | Cancer Network
    Despite breast tumors’ lower mutational loads than lung cancers and melanoma—cancers in which immunotherapy have shown particular promise—breast cancers are nevertheless immunogenic.
    www.cancernetwork.com />j

    VIDEO: Vaccines, combination therapy hold most promise for optimizing immunotherapy in breast cancer
    Publish date: March 11, 2017
    Damian McNamara
    Oncology Practice

    NeuVax™ + trastuzumab, HER2 1+,2+

    Disease: Breast Cancer
    Status: Enrolling Patients
    Trial Design: Phase 2b

    This investigator-sponsored trial (IST) is ongoing with NeuVax in combination with trastuzumab (Herceptin®; Genentech/Roche). The combination of trastuzumab and NeuVax has been shown pre-clinically and in a pilot study to be synergistic. Our Phase 2b clinical trial is a randomized, multicenter, investigator-sponsored, 300 patient study enrolling HER2 1+ and 2+, HLA A2+, A3+, A24 and/or A26, node positive, and high-risk node negative patients. Eligible patients are randomized to receive NeuVax + GM-CSF + trastuzumab or trastuzumab + GM-CSF alone. The primary endpoint of the study is disease-free survival. Genentech/Roche is providing the trastuzumab and partial funding for this trial.

    Data presented in October 2016 demonstrated that this novel combination of trastuzumab and NeuVax with HER2 low-expressing patients is well tolerated and the cardiac effects of trastuzumab are not impacted by the addition of NeuVax. In February 2017, the Data Safety Monitoring Board (DSMB) reported that there were no safety concerns with the trial and the trial is not futile. The recommendation from the DSMB was to continue the trial with one revision to the statistical analysis plan regarding the timing of the pre-specified interim analysis. Given the lengthy duration of enrollment for the trial, the DSMB determined that the pre-specified interim efficacy analysis be moved up from 12 months to 6 months after the last patient is enrolled. Completion of enrollment is expected in the second quarter of 2017; therefore, the DSMB expects to perform the interim efficacy analysis near the end of 2017.

    This investigator-sponsored trial is a clinical collaboration between Galena, Genentech/Roche, and the Henry M. Jackson Foundation.
    Trial Design and Eligibility

    ClinicalTrials.gov: Identifier NCT01570036

    For more information, please contact clinicaltrials@galenabiopharma.com
    About the disease

    According to the National Cancer Institute (NCI), over 230,000 women in the U.S. are diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have decreased breast cancer mortality in the U.S., metastatic breast cancer remains incurable. Approximately 75% to 80% of breast cancer patients have tissue test positive for some increased amount of the HER2 receptor, which is associated with disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer patients-those with HER2 immunohistochemistry (IHC) 3+ disease, or IHC 2+ and fluorescence in situ hybridization (FISH) amplified-have a HER2 directed, approved treatment option available after their initial standard of care. This leaves the majority of breast cancer patients with low-to-intermediate HER2 expression (IHC 1+, 2+) ineligible for therapy and without an effective targeted treatment option to prevent cancer recurrence.

    New cases of breast cancer occur at an annual rate of 125 per 100,000 women in the U.S., with an estimated 246,660 new cases and 40,450 deaths in 2016. Approximately 89.7% of breast cancer patients are expected to survive five years after diagnosis. Approximately 12.4% of women will be diagnosed with breast cancer at some point during their lifetime (2011 – 2013 data). The prevalence data from 2013 showed an estimated 3,053,450 women living with breast cancer in the United States. Source: National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://www.galenabiopharma.com/presentations-and-publications/neuvax-nelipepimut-s/default.aspx

    Combinations ‘Likely the Way Forward’ for Breast Cancer Immunotherapy Research | Cancer Network
    Despite breast tumors’ lower mutational loads than lung cancers and melanoma—cancers in which immunotherapy have shown particular promise—breast cancers are nevertheless immunogenic.
  • James pumped the DFS of the Neuvax P3 trial, just before the IDMC shut down the sham.
    I've seen this horror flick before.
    James is always wrong.
  • Sally Miles, the IDMC shut down the Neuvax trial because the placebo was more efficacious than Neuvax. Prior to that Neuvax failed in trial for Apthera, so they dumped the junk. Galena bought it for $7M.
    Wake up, Sally, Neuvax DOESN'T WORK , it has NEVER WORKED! Neuvax FAILED IN TRIALS. Posters are pointing out the FAILURES. They are not hoping for failure.
    Nobody needs a FAILED drug, Comprende?
  • Gale settled another lawsuit yesterday for the share count controversy
  • GALE has just seen the last of the selling. Looks like a potential push higher is in store. Yo you should really check out awesom_stocks, they seem on point with their stocks.
  • pnnk is right:
    Pumped by Ugly Beth and James2tx:
    "Five-year DFS was 94.6% in optimally dosed patients (P = 0.05 versus the CG) and 87.1% in suboptimally dosed patients. A voluntary booster program was initiated, and among the 21 patients that were optimally boosted, there was only one recurrence (DFS = 95.2%)."
    Then in the P3 trial, the placebo outperformed Neuvax.
    Oh my!!!!!

    Now James is once again pumping the bogus DFS."
  • Whys the stock down 03 in after hours?
  • Last week, on July 12th, over one million shares were traded, the stock couldn't break 60 pennies, and James keeps posting about a short squeeze. 😂😂😂
  • $17k worth of stock traded so far. Someone must know something right James?
  • Cayman to get $0.35 shares. Why would anyone pay more for Galena shares?
    "deliver aggregate consideration in shares of Common Stock and cash in satisfaction of the applicable holder redemption amount as follows: (i) the number of shares of Common Stock equal to the quotient obtained by dividing such holder redemption amount and $0.35 (each such share having a deemed value per share at the Stock Payment Price that would have been in effect but for the Minimum Stock Payment Price Condition of $0.35 per share)"
  • September will be crunch time for either DELISTING or REVERSE SPLIT.
    What is preferred?